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Hepatitis C virus (HCV) non-structural protein 2 (NS2) encodes an autoprotease activity that is essential
for virus replication and thus represents an attractive anti-viral target. Recently, we demonstrated that a
series of epoxide-based compounds, previously identiﬁed as potent inhibitors of the clotting factor, FXIII,
also inhibited NS2-mediated proteolysis in vitro and possessed anti-viral activity in cell culture models.
This suggested that a selective small molecule inhibitor of the NS2 autoprotease represents a viable
prospect. In this independent study, we applied a structure-guided virtual high-throughput screening
approach in order to identify a lead-like small molecule inhibitor of the NS2 autoprotease. This screen
identiﬁed a molecule that was able to inhibit both NS2-mediated proteolysis in vitro and NS2-dependent
genome replication in a cell-based assay. A subsequent preliminary structureeactivity relationship (SAR)
analysis shed light on the nature of the active pharmacophore in this compound and may inform further
development into a more potent inhibitor of NS2 mediated proteolysis.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Hepatitis C virus (HCV) infects 2.8% of the worldwide popula-
tion, with 85% of cases progressing to chronic infection (Webster
et al., 2015), associated with both liver cirrhosis and hepatocellu-
lar carcinoma. HCV possesses a 9.6 kb positive sense RNA genome
which encodes a single 3000 amino acid polyprotein and viral
replication is absolutely dependent on proteolytic processing of this
polyprotein into mature proteins. Host proteases cleave between
the virion structural proteins (Core, E1 and E2), the p7 viroporin
and p7-NS2 junction. Two virally-encoded protease activities
complete processing of the remaining non-structural (NS) proteins
NS2, NS3, NS4A, NS4B, NS5A and NS5B. An autoprotease activity
performs cleavage at the NS2-NS3 junction, while the remaining
junctions are processed by the NS3 serine protease.structural; SGR, subgenomic
Fulminant Hepatitis 1; EC50,
eagent 1; PLB, Passive Lysis
tural Molecular Biology, Uni-
, C.W.G.Fishwick@leeds.ac.uk
r B.V. This is an open access articleHCV therapy has advanced rapidly with the development of
direct acting anti-virals (DAAs) which target polyprotein processing
or genome replication. DAAs target two virally encoded enzymes;
the NS3 protease and the NS5B RNA-dependent RNA polymerase,
but also NS5A (which lacks enzyme activity) through a poorly
deﬁned mode of action (Webster et al., 2015). While the success of
these therapies has been encouraging to date, the long term
response and potential for viral resistance remain to be seen.
Until recently, the only HCV encoded enzyme activity to which
small molecule inhibitors have not been reported is the autopro-
tease activity encoded within NS2 and responsible for cleavage at
the NS2-NS3 junction. NS2 is a 23 kDa protein that in addition to
autoprotease activity has an independent, albeit poorly deﬁned,
role in virus assembly (Jones et al., 2007; Ma et al., 2011;
Shanmugam et al., 2015). It comprises an N-terminal trans-
membrane domain and a C-terminal cytoplasmic domain, the latter
of which contains the cysteine autoprotease activity. The enzyme
activity is encoded within NS2 but is enhanced by elements from
the NS3 N-terminus (Schregel et al., 2009). NS2-NS3 cleavage is
essential in the virus lifecycle (Jones et al., 2007; Kolykhalov et al.,
2000; Welbourn et al., 2005). Although NS2 plays no direct role in
genome replication processing of NS3 from an NS2-NS3 precursor
is required for an NS3-mediated function which is essential in theunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Due to its essential nature in the HCV lifecycle, the NS2 auto-
protease represents an attractive therapeutic target (Lorenz, 2010;
Rice, 2011). In this regard, we recently reported that a series of
epoxide-containing small molecule inhibitors of the trans-
glutaminase FXIII-A (Avery et al., 2015) were also able to inhibit NS2
mediated proteolysis both in vitro and in cell-based systems (Shaw
et al., 2015). To further explore the potential to inhibit the HCV NS2
autoprotease a structure-guided virtual high-throughput screening
approach was employed to identify a lead-like small molecule in-
hibitor. This molecule represents a ﬁrst-in-class anti-viral agent
with activity against infectious HCV in cell culture and provides
evidence that inhibitors of virally encoded auto-proteases are a
viable prospect.
2. Materials and methods
2.1. Compounds
Compounds 160 (ID: 38490315), 160e3, 160e4, 160e5, 160e6,
160e7, 160e8 and 160e9were from ChemBridge Corporation. SM-
1, SM-2 and Telaprevir were from KeyOrganics, Sigma Aldrich and
MedChem Express respectively. 160e1 and 160e2 were syn-
thesised in-house (Supplementary Materials). All compounds were
conﬁrmed using a VG Autospec mass spectrometer with electron
spray ionisation (ES) at 70 eV.
2.2. In silico enrichment of screening libraries
C-terminal residues were sequentially removed from the active
site cavity of the post-cleaved NS2 protease domain structure (PDB:
2HD0) using Maestro (Schrodinger) to produce the modelsFig. 1. Identiﬁcation of a lead-like inhibitor of the NS2 autoprotease. A) Chemical structure
incubated in refolding buffer (Shaw et al., 2015) in the presence of the indicated concentratio
assayed by western blot with an anti-FLAG antibody. C) SGR-feo-NS2-5B(JFH-1) harbouring
determination of luciferase activity. Cell viability was measured simultaneously by ATPLite
duplicate. D) Addition of 160 (10 mM) reduces luciferase activity in SGR-feo-NS2-5B(Con1) h
SGR-feo-NS3-5B(Con1) harbouring cells. Data show the mean ± SD of two experiments
determined by the Student's t test (*p ¼ 0.0006).NS2DP1P2, NS2DP1P5 and NS2DP1P10. Virtual screening was per-
formed using eHITS (SymBioSys) to dock and score a library of
>5  105 commercially available lead-like molecules. Additionally,
SPROUT (Gillet et al., 1994) was employed to construct models of
molecules predicted to form favourable interactions. Top scoring
molecules were expanded using ROCS 3.2.0.4 (OpenEye Scientiﬁc
Software, Santa Fe, NM. http://www.eyesopen.com) (Hawkins et al.,
2007) and ﬁltered by favourable modelled binding pose, structural
diversity and cLogP to yield a library of 200 compounds.
2.3. Screening of small molecules in vitro
NS2-NS3-FLAG (JFH-1 isolate, genotype 2a) was puriﬁed, and
proteolysis reactions were performed as previously described
(Shaw et al., 2015). Compounds were added to reactions prior to
addition of NS2-NS3-FLAG by dilution from DMSO stocks (ﬁnal
DMSO 0.75%). Reactions were incubated at room temperature for
16 h, terminated by addition of Laemmli buffer and the NS3-FLAG
proteolysis product quantiﬁed by western blot using M2 anti-
FLAG monoclonal antibody (Sigma Aldrich) and IRDye 680RD
Donkey anti-Mouse (LI-COR Biosciences) on an Odyssey imager (LI-
COR). NS3-FLAG was normalised to DMSO control and a non-linear
regression ﬁtted with Prism 6 (GraphPad) to determine 50% effec-
tive concentration (EC50).
2.4. Cell based screening of small molecules
Selection and maintenance of Huh7.5 cells stably harbouring
SGR-feo-NS3-5B (Wyles et al., 2009, 2007) or SGR-feo-NS2-5B
derived from JFH-1 (genotype 2a) and Con1 (genotype 1b) has
previously been reported (Shaw et al., 2015). Cells were maintained
in Dulbecco's modiﬁed Eagle's medium (DMEM) supplementedof active compound 160. B) Puriﬁed recombinant NS2-NS3-FLAG fusion protein was
ns of 160. The presence of the precursor and the NS2 proteolytic product NS3-FLAG was
Huh7.5 cells were treated with the indicated concentrations of 160 for 48 h prior to
assay. Data represent the mean ± SD of one representative experiment performed in
arbouring Huh7.5 cells relative to DMSO control without affecting luciferase activity in
performed in triplicate (RLU e Relative Luciferase Units). Statistical signiﬁcance was
Table 1
Structure activity relationship analysis of 160. EC50 calculated from 10-point dose
response treatment of JFH-1 NS2-3 in vitro proteolysis reactions (Supplementary
Fig. 2).* Mean ± SD of three experimental repeats.
Compound Structure JFH1 NS2-3 EC50 (mM)
160 44.6 ± 6.2 *
160e1 43.0 ± 0.5 *
160e2 68.4 ± 5.6 *
160e3 >300
160e4 >300
160e5 >300
160e6 >300
160e7 >300
160e8 >300
160e9 >300
SM-1 >300
SM-2 >300
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non-essential amino acids and 300 mg/ml G418 in a humidiﬁed
incubator at 37 C in 5% CO2. For screening, 2  104 cells/well were
seeded in a 96-well plate in the absence of G418 and compounds
were added to 10 mM ﬁnal concentration by dilution from DMSO
stocks. At 72 h, cells were washed in PBS and lysed in 30 ml/well
Passive Lysis Buffer (PLB: Promega). Luciferase activity was quan-
tiﬁed by automated addition of 40 ml LarI reagent (Promega) and
light emission recorded over 6 s using a BMG Labtech Fluostar plate
reader. Statistical signiﬁcance was determined using the Student's t
test.
2.5. Determination of effective concentrations against SGR
For transient SGR experiments, in vitro transcripts (2 mg) of
ﬁreﬂy luciferase-containing SGR were electroporated into 4  106
Huh7.5 cells (Blight et al., 2002) or Huh7 cells at 950 mF and 270 V.
2  104 cells/well were seeded in a 96 well plate. At 4 h post
electroporation (h.p.e.) media was replaced with media containing
compounds.
For cytotoxicity assay, media was removed and cells were
incubated in 1 mM thiazolyl blue tetrazolium bromide (MTT) for
>2 h. MTT crystals were resuspended in 100 ml DMSO and absor-
bance at 570 nm quantiﬁed using an inﬁnite F50 plate reader
(Tecan). Alternatively, cytotoxicity was analysed using the ATPLite
kit following the manufacturer's instructions, with light emission
quantiﬁed using a BMG Labtech Fluostar plate reader.
Fireﬂy luciferase was measured as in Section 2.4. Data was
normalised to DMSO controls and EC50/CC50 determined using
Prism 6 (GraphPad).
2.6. Western blot analysis of cellular lysates
2  106 cells were seeded in a 10 cm dish and incubated as
indicated. Cells were washed in PBS and lysed in 100 ml PLB. Clar-
iﬁed lysates were analysed by 15% SDS-PAGE and western blot.
Anti-GAPDH (Abcam) (1:20,000) or anti-NS5A (Macdonald et al.,
2003) (1:5000) were followed by IRDye 680RD Donkey anti-
Mouse or IRDye 800CW Donkey anti-Rabbit (LI-COR BioSciences)
(1:10,000) respectively. Imaging was performed using an Odyssey
Imager (LI-COR).
2.7. Determination of effective concentrations against HCVcc
For HCVcc experiments, 5 mg of Jc1-NLuc (Amako et al., 2015)
transcript was electroporated into Huh7.5 cells and treated with
compound as described in Section 2.5. Cytotoxicity or NanoLuc
(NLuc) activity was measured at 48 h incubation with compound.
Cells were lysed as in Section 2.4. Following the addition of 50 ml/
well Nano-Glo Luciferase Assay Substrate (Promega) light emission
was recorded using a BMG Labtech Fluostar plate reader and data
analysed as in Section 2.5.
3. Results
3.1. Identiﬁcation of a lead-like small molecule inhibitor of the NS2
autoprotease
To explore the viability of NS2 autoprotease inhibitors as a novel
class of anti-virals, we exploited the availability of a high (2.3 Å)
resolution structure representing the post-cleavage NS2 autopro-
tease (Lorenz et al., 2006). A library of lead-like small molecules
was enriched using structure-guided virtual high-throughput
screening (vHTS) of >5  105 commercially available compounds
through a combination of eHITS (Zsoldos et al., 2006) and SPROUT
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targeted to the NS2 autoprotease structure wherein C-terminal
residues were sequentially removed to expose the active site cavity
(Supplementary Fig. 1). High scoring compounds with attractive
lead-like properties were then screened for activity against NS2-
mediated proteolysis in two independent assays.
Firstly, compounds were tested for the ability to block produc-
tion of a substrate product of the NS2 autoprotease in an in vitro
assay. This assay, using a recombinant NS2-NS3-FLAG precursor
puriﬁed under denaturing conditions, measured NS2 autoprotease
activity using quantitative western blot to monitor a proteolysis
product (NS3-FLAG) (Foster et al., 2010; Shaw et al., 2015; Tedbury
and Harris, 2007).
Additionally, compounds were tested for the ability to specif-
ically perturb NS2-dependent HCV genome replication in a cell-
based assay. Compounds were tested against cells stably harbour-
ing a HCV sub-genomic replicon (SGR) comprising either NS2-5B or
NS3-5B with a ﬁreﬂy luciferase-neomycin phosphotransferase re-
porter (Shaw et al., 2015; Wyles et al., 2009, 2007). In this system,
SGR-feo-NS2-5B encodes NS3 as part of an NS2-NS3 precursor
within the translated polyprotein, hence genome replication is
dependent on the NS2 autoprotease activity. In contrast, SGR-feo-
NS3-5B lacks the NS2 coding sequence and is thus independent
of NS2 autoprotease activity.Fig. 2. Activity of 160 and analogues against NS2-dependent genome replication. SGR-lu
indicated concentrations of 160 (A) or the inactive derivatives 160e3 (B) or 160e4 (C) at 4
measured and plotted relative to DMSO control. Data represent the mean ± SD of one represe
determined across several experimental repeats. Additional primary data is presented in SuThe compound (2R, 3R)-3-amino-10-[(1-methylcyclohexyl)
carbonyl]-2,3,dihydrospiro[indene-1,40-piperidine]-2-ol (termed
160 henceforth) (Fig. 1A) was identiﬁed as a ‘hit’ in both of these
assays. Addition of 160 to the in vitro NS2 autoprotease assay
reduced production of the NS3-FLAG product in a dose-responsive
manner with an EC50 of 39 mM (Fig. 1B). In the cell-based assay,160
also inhibited luciferase activity in cells stably harbouring SGR-feo-
NS2-5B(JFH-1) with an EC50 of 43.4 mM (Fig.1C). To conﬁrm that the
activity of 160 was not restricted to the genotype 2a JFH-1 isolate,
we showed that luciferase activity in Huh7.5 cells stably harbouring
the genotype 1b derived SGR-feo-NS2-5B(Con1) was signiﬁcantly
reduced by 160 (10 mM) relative to DMSO control, with no effect on
luciferase activity from SGR-feo-NS3-5B(Con1) (Fig. 1D). Impor-
tantly therefore, 160 only reduced reporter activity when genome
replicationwas dependent on NS2-mediated processing at the NS2-
NS3 junction of the polyprotein.
To explore the requirements for activity against the NS2 auto-
protease in vitro, a range of structurally similar compounds were
tested, sourced from both in-house synthesis of variants, and via
purchase of commercially available compounds judged to be
potentially similar to compound 160 using the ROCS software.
Molecules 160e1 and 160e2were synthesised in-house (for details
see supplementarymaterial), while 160e3 to 160e9, SM-1 and SM-
2were commercially available. Compounds were tested for activityc-NS2-5B(JFH-1) RNA was electroporated into Huh7.5 cells which were treated with
h.p.e. At 48 h.p.e cell viability was quantiﬁed by MTT assay and luciferase activity was
ntative experiment performed in duplicate. (D) EC50 and CC50 for indicated compounds
pplementary Fig. 3. Mean ± SD are reported.
Fig. 3. 160 inhibits replication of a NS2-5B sub-genomic replicon in the absence of
cytotoxicity. A) Huh7.5 cells treated with DMSO control or an EC50 concentration of 160
(25 mM) for 48 h before quantifying viable cells using the ATPLite assay. Data is nor-
malised to DMSO control and represents the mean ± SD of three experimental repeats
performed in triplicate. B) SGR-luc-NS2-5B(JFH-1) or a polymerase defective control
(GND) were electroporated into Huh7.5 cells prior to treatment with DMSO control,
160 (25 mM) or Telaprevir (100 nM) and assay for luciferase activity at the indicated
time points. Data represent the mean ± SD of two experimental repeats performed in
triplicate. Statistical signiﬁcance was determined by the Student's t test (***p  0.0001,
**p  0.0002, *p  0.0023). C) Cell lysates from B at 52 h.p.e. were analysed for NS5A
and GAPDH by western blot.
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compounds had no effect on production of the NS3-FLAG proteol-
ysis product when added after the proteolysis reaction was com-
plete (data not shown), conﬁrming that they acted to inhibit
proteolysis rather than affecting NS3-FLAG detection by western
blot.
As summarised in Table 1, we were able to establish some pre-
liminary structureeactivity relationship (SAR) analysis from the
small library of molecules that were screened. Thus, activity of 160
against the NS2 autoprotease in vitro did not require the presence of
the primary alcohol and amine groups at the stereocentres of the
indene core in 160. However, activity was found to be crucially
dependent on the presence of the cyclohexane portion in 160 and is
enhanced by the presence of a 1-(methylcyclohexyl) moiety as in
160 and 160e1. This would indicate that, whilst hydrophobic in-
teractions between this portion of the inhibitor and protein would
appear to be important, there is also a requirement for shape
complementarity. These observations begin to map the features of
160 which contribute to activity against the NS2 autoprotease.
3.2. Activity of 160 against a transient NS2-5B SGR
Inhibition of both NS2-mediated proteolysis in vitro (Fig. 1B),
and NS2-dependent HCV genome replication in a cell based assay
(Fig. 1C) by 160 exhibited similar EC50 values (39/43.4 mM
respectively). We considered that the relatively low efﬁcacy of 160
in the cell-based assay might be due to the fact that these cells had
been selected to harbour a stable SGR and thus they contained pre-
existing, replication complexes whose activity would not be
dependent on NS2-3 cleavage. To test this we performed a transient
replication assay in which in vitro transcripts of a JFH-1 derived
luciferase-containing SGR (SGR-luc-NS2-5B(JFH-1)) (Tedbury et al.,
2011) were electroporated into the HCV permissive Huh7.5 cell line
(Blight et al., 2002) and treated for 48 h with a range of concen-
trations of 160. Cytotoxicity was quantiﬁed by MTT assay and
replication assayed by measuring luciferase activity. A representa-
tive assay is presented (Fig. 2A), demonstrating that treatment with
160 produced a dose responsive reduction in luciferase activity.
Over four biological replicates (Fig. 2D) 160 did indeed exhibit an
improved EC50 of 12.0 ± 6.4 mM, compared to the activity observed
in the stable SGR-harbouring cells. At higher concentrations of 160,
some cytotoxic effects were observed (Fig. 2A, D). However, due to
the limitation in the achievable concentration of 160 and de-
rivatives (300 mM), it was not possible to calculate an accurate CC50
value, although the data indicate a selectivity index of >5.
In contrast, 160e3 and 160e4, derivatives inactive against the
NS2 autoprotease in vitro (Supplementary Fig. 2), did not exhibit
any speciﬁc effect against replication. For 160e3 luciferase activity
closely correlated with the degree of cytotoxicity indicating a lack
of any speciﬁc effect on SGR genome replication (Fig. 2B, D). In
contrast 160e4 had no cytotoxicity or effect on luciferase activity
up to 200 mM (Fig. 2C, D).
To conﬁrm an inhibitory effect of 160 against NS2-dependent
genome replication in the absence of cytotoxic effects, SGR-luc-
NS2-5B(JFH-1) electroporated cells were treated with a concen-
tration of 160 (25 mM) that had no observed cytotoxicity as
measured either by MTT (Fig. 2A, Supplementary Fig. 3), or ATPlite
assay (Fig. 3A). 160 was added 4 h.p.e and luciferase activity was
monitored every 4 h for a further 48 h. Addition of 160 led to a
reduction in luciferase activity and a lag in detectable luciferase
activity relative to DMSO control (Fig. 3B). Addition of an inter-
mediate concentration (100 nM) of Telaprevir produced a compa-
rable proﬁle.
Cell lysates at 52 h.p.e were analysed by western blot for NS5A
and GAPDH. Both 160 and Telaprevir caused a comparablereduction in NS5A relative to DMSO control (Fig. 3C). These results
demonstrate that 160 inhibits NS2-dependent HCV genome repli-
cation in the absence of cytotoxicity.
3.3. 160 exhibited anti-viral activity
We next assessed the antiviral activity of 160 in an infectious
system, using a derivative of the genotype 2a chimeric Jc1 construct
that encodes a Nano-luciferase reporter (Jc1-NLuc) (Amako et al.,
J. Shaw et al. / Antiviral Research 124 (2015) 54e60 592015). Jc1-NLuc RNA was electroporated into Huh7.5 cells and
treated with 160 from 4 to 48 h.p.e. Three biological replicates of
this experiment are shown in Fig. 4 and demonstrate that 160
treatment resulted in a dose-dependent reduction in NLuc reporter
activity with an EC50 of 17.3 ± 8.1 mM that was comparable to that
observed against SGR (Fig. 4A). Cytotoxicity of 160 was simulta-
neously assessed byMTTassay (Fig. 4B) and was comparable to that
observed in SGR (Fig. 2). These ﬁndings demonstrate that the small
molecule 160, which blocks NS2-NS3 processing in vitro, can
function as an anti-viral compound.
4. Discussion
Recent advances in all-oral, interferon-free HCV therapeutic
regimes have involved the use of DAAs targeting HCV-encoded
enzyme activities; namely inhibitors targeting NS3/4A proteaseFig. 4. Anti-viral activity of 160. Jc1-NLuc RNA was electroporated into Huh7.5 cells and tre
assess anti-viral effects. B) 48 h.p.e cellular metabolism was quantiﬁed by MTT assay (Cell
periments performed in duplicate shown. Mean EC50 ¼ 17.3 ± 8.1 mM. Mean CC50 ¼ 109.8and NS5B RNA polymerase. Small molecule inhibitors of the NS3
helicase have also been reported but remain in pre-clinical stages.
Thus the only HCV-encoded enzyme activity which has not been
targeted with DAAs is the protease activity encoded within the C-
terminus of NS2.
We report the identiﬁcation of a lead-like small compound,160,
which blocks NS2-mediated proteolysis at the NS2-NS3 junction
in vitro. SAR analysis has begun to inform on the active pharma-
cophore of this series: 160, and its active analogues 160e1 and
160e2, represent an interesting chemotype that could be expanded
to explore additional, more potent, inhibitors of NS2-mediated
proteolysis. Treatment with 160 reduced reporter activity in a
SGR system where genome replication was dependent on NS2
autoprotease activity (SGR-NS2-5B) without affecting reporter ac-
tivity in a SGR system that lacks NS2 (SGR-NS3-5B) (Fig. 1B). The
EC50 of 160 against SGR-NS2-5B was 12.0 ± 6.4 mM (Fig. 2D), anated with a range of concentrations of 160. A) 48 h.p.e. NLuc activity was quantiﬁed to
viability, MTT). Data is normalised to DMSO control with the mean ± SD of three ex-
± 40.0 mM.
J. Shaw et al. / Antiviral Research 124 (2015) 54e6060improved potency compared to previously reported NS2 inhibitors
(Shaw et al., 2015). Importantly, 160 also inhibited viral replication
in the context of infectious virus, reducing reporter activity at
concentrations where cellular metabolism remains unaffected
(Fig. 4).
The activity of 160 had a narrow selectivity index (>5), as
modest cytotoxic effects were observed at  95 mM and at the
maximal attainable concentration (300 mM), cell viability was
reduced to 40%. However, at an intermediate concentration of 160
(25 mM) both reporter activity and NS5A expression were reduced
in the absence of detectable cytotoxicity (Fig. 3). Furthermore, SAR
demonstrated that the derivatives 160e3 and 160e4 were inactive
in both the in vitro NS2 autoprotease and cell-based NS2-
dependent replication assays. 160e3 only showed reduced re-
porter activity at  95 mMwhich correlated with decreased cellular
metabolism, hence the compound possessed no selective anti-viral
activity. This suggests that a hydrophobic group in place of the 1-
methyl cyclohexane portion of 160 was associated with cytotox-
icity. However, while both an isopropyl or 1-methyl substituted
cyclohexane at this position are responsible for cytotoxic effects,
only a 1-methyl cyclohexane moiety imparts activity against NS2-
mediated proteolysis in vitro and against NS2-dependent HCV
genome replication. Further modiﬁcations to this region may help
to increase the selectivity index of future compounds.
In conclusion, our study has identiﬁed a small molecule (160)
that selectively inhibits the cleavage of the NS2-3 precursor.
Although the potency of 160 is not sufﬁcient to impact on current
therapeutic regimes, it provides a starting point for further devel-
opment, and importantly also represents proof of principle that this
proteolytic cleavage is a valid and tractable target for future anti-
viral strategies to enhance the breadth of HCV therapies.
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